BLPH Bellerophon Therapeutics, Inc.

1.43
-0.07  -5%
Previous Close 1.50
Open 1.54
Price To book 2.64
Market Cap 45.82M
Shares 32,039,000
Volume 384,959
Short Ratio 2.09
Av. Daily Volume 1,101,450

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated May 2016. Data presented at American Thoracic Society (ATS) Conference, May 21 2017. Phase 2b planned.
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 3 commenced enrollment June 2016. Interim analysis due 4Q 2017 with top-line data due mid-2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2 initiated 3Q 2016. Data due mid-2017.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)

Latest News

  1. Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference
  2. Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Bellerophon Therapeutics
  3. Bellerophon Therapeutics posts 1Q loss
  4. Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update
  5. Bellerophon Announces $3.0 Million Registered Direct Offering
  6. Bellerophon to Present Positive Clinical Data on INOpulse® at the American Thoracic Society 113th International Conference
  7. Bellerophon Slumps on Underwhelming INOpulse Data
  8. Clinical Data on INOpulse® Presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT)
  9. Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation
  10. The Difference Between Spectacular News and No News
  11. Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
  12. LifeSci Capital Initiates Coverage of Bellerophon Therapeutics
  13. These 5 Stocks Under $10 Could Make You a Lot of Money
  14. INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Bellerophon Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm
  15. Robbins Arroyo LLP is Investigating the Officers and Directors of Bellerophon Therapeutics, Inc. (BLPH) on Behalf of Shareholders
  16. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellerophon Therapeutics, Inc. (BLPH)

SEC Filings

  1. 8-K - Current report 17860938
  2. D - Notice of Exempt Offering of Securities 17856920
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 17853908
  4. 8-K - Current report 17841310
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17840981
  6. 8-K - Current report 17835987
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17832474
  8. 8-K - Current report 17818697
  9. 8-K - Current report 17805216
  10. 8-K - Current report 17798591